通过正电子发射断层扫描成像骨骼转移瘤的新型[68Ga]Ga标记NOTA共轭双膦酸盐的合成、质量控制和从实验室到实验室的转化。

IF 2.4 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-02-01 Epub Date: 2024-02-09 DOI:10.1089/cbr.2023.0077
Sudipta Chakraborty, Sucheta Chatterjee, Rubel Chakravarty, Haldhar D Sarma, Raviteja Nanabala, Dibakar Goswami, Ajith Joy, Maroor Raghavan Ambikalamajan Pillai
{"title":"通过正电子发射断层扫描成像骨骼转移瘤的新型[68Ga]Ga标记NOTA共轭双膦酸盐的合成、质量控制和从实验室到实验室的转化。","authors":"Sudipta Chakraborty, Sucheta Chatterjee, Rubel Chakravarty, Haldhar D Sarma, Raviteja Nanabala, Dibakar Goswami, Ajith Joy, Maroor Raghavan Ambikalamajan Pillai","doi":"10.1089/cbr.2023.0077","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background</i></b>: Early detection of skeletal metastasis is of great interest to determine the prognosis of cancer. Positron emission tomography-computed tomography (PET-CT) imaging provides a better temporal and spectral resolution than single photon emission computed tomography-computed tomography (SPECT-CT) imaging, and hence is more suitable to detect small metastatic lesions. Although [<sup>18</sup>F]NaF has been approved by U.S. FDA for a similar purpose, requirement of a medical cyclotron for its regular formulation restricts its extensive utilization. Efforts have been made to find suitable alternative molecules that can be labeled with <sup>68</sup>Ga and used in PET-CT imaging. <b><i>Objective:</i></b> The main objective of this study is to synthesize and evaluate a new [<sup>68</sup>Ga]Ga-labeled NOTA-conjugated geminal bisphosphonate for its potential use in early detection of skeletal metastases using PET-CT. <b><i>Methods:</i></b> The authors performed a multistep synthesis of a new NOTA-conjugated bisphosphonic acid using thiourea linker and radiolabeled the molecule with <sup>68</sup>Ga. The radiolabeled formulation was evaluated for its <i>in vitro</i> stability, affinity for hydroxyapatite (HA) particles, preclinical biodistribution in animal models, and PET-CT imaging in patients. <b><i>Results:</i></b> The bifunctional chelator (NOTA)-conjugated bisphosphonate was synthesized with 97.8% purity and radiolabeled with <sup>68</sup>Ga in high yield (>98%). The radiolabeled formulation was found to retain its stability <i>in vitro</i> to the extent of >95% up to 4 h in physiological saline and human serum. The formulation also showed high affinity for HA particles <i>in vitro</i> with <i>K<sub>d</sub></i> = 907 ± 14 mL/g. Preclinical biodistribution studies in normal Wistar rats demonstrated rapid and almost exclusive skeletal accumulation of the complex. PET-CT imaging in a patient confirmed its ability to detect small metastatic skeletal lesions. <b><i>Conclusions:</i></b> The newly synthesized [<sup>68</sup>Ga]Ga-labeled NOTA-conjugated bisphosphonate is a promising radiotracer for PET-CT imaging for skeletal metastases.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"92-101"},"PeriodicalIF":2.4000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis, Quality Control, and Bench-to-Bed Translation of a New [<sup>68</sup>Ga]Ga-Labeled NOTA-Conjugated Bisphosphonate for Imaging Skeletal Metastases by Positron Emission Tomography.\",\"authors\":\"Sudipta Chakraborty, Sucheta Chatterjee, Rubel Chakravarty, Haldhar D Sarma, Raviteja Nanabala, Dibakar Goswami, Ajith Joy, Maroor Raghavan Ambikalamajan Pillai\",\"doi\":\"10.1089/cbr.2023.0077\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Background</i></b>: Early detection of skeletal metastasis is of great interest to determine the prognosis of cancer. Positron emission tomography-computed tomography (PET-CT) imaging provides a better temporal and spectral resolution than single photon emission computed tomography-computed tomography (SPECT-CT) imaging, and hence is more suitable to detect small metastatic lesions. Although [<sup>18</sup>F]NaF has been approved by U.S. FDA for a similar purpose, requirement of a medical cyclotron for its regular formulation restricts its extensive utilization. Efforts have been made to find suitable alternative molecules that can be labeled with <sup>68</sup>Ga and used in PET-CT imaging. <b><i>Objective:</i></b> The main objective of this study is to synthesize and evaluate a new [<sup>68</sup>Ga]Ga-labeled NOTA-conjugated geminal bisphosphonate for its potential use in early detection of skeletal metastases using PET-CT. <b><i>Methods:</i></b> The authors performed a multistep synthesis of a new NOTA-conjugated bisphosphonic acid using thiourea linker and radiolabeled the molecule with <sup>68</sup>Ga. The radiolabeled formulation was evaluated for its <i>in vitro</i> stability, affinity for hydroxyapatite (HA) particles, preclinical biodistribution in animal models, and PET-CT imaging in patients. <b><i>Results:</i></b> The bifunctional chelator (NOTA)-conjugated bisphosphonate was synthesized with 97.8% purity and radiolabeled with <sup>68</sup>Ga in high yield (>98%). The radiolabeled formulation was found to retain its stability <i>in vitro</i> to the extent of >95% up to 4 h in physiological saline and human serum. The formulation also showed high affinity for HA particles <i>in vitro</i> with <i>K<sub>d</sub></i> = 907 ± 14 mL/g. Preclinical biodistribution studies in normal Wistar rats demonstrated rapid and almost exclusive skeletal accumulation of the complex. PET-CT imaging in a patient confirmed its ability to detect small metastatic skeletal lesions. <b><i>Conclusions:</i></b> The newly synthesized [<sup>68</sup>Ga]Ga-labeled NOTA-conjugated bisphosphonate is a promising radiotracer for PET-CT imaging for skeletal metastases.</p>\",\"PeriodicalId\":55277,\"journal\":{\"name\":\"Cancer Biotherapy and Radiopharmaceuticals\",\"volume\":\" \",\"pages\":\"92-101\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Biotherapy and Radiopharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/cbr.2023.0077\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2023.0077","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:早期检测骨骼转移对确定癌症预后具有重要意义。与单光子发射计算机断层扫描(SPECT-CT)相比,正电子发射计算机断层扫描(PET-CT)成像具有更好的时间分辨率和光谱分辨率,因此更适合检测小的转移病灶。虽然[18F]NaF 已获美国 FDA 批准用于类似目的,但其常规制剂需要医用回旋加速器,这限制了其广泛应用。人们一直在努力寻找可使用 68Ga 标记并用于 PET-CT 成像的合适替代分子。研究目的本研究的主要目的是合成和评估一种新的[68Ga]Ga标记的NOTA共轭宝石双膦酸盐,以便利用PET-CT对骨骼转移瘤进行早期检测。方法:作者使用硫脲连接体多步合成了一种新的NOTA共轭双膦酸,并用68Ga对该分子进行了放射性标记。对放射性标记制剂的体外稳定性、与羟基磷灰石(HA)颗粒的亲和性、动物模型的临床前生物分布以及患者的 PET-CT 成像进行了评估。结果显示双功能螯合剂(NOTA)共轭双膦酸盐的合成纯度为 97.8%,并以高产率(>98%)用 68Ga 进行了放射性标记。研究发现,放射性标记的制剂在体外生理盐水和人体血清中的稳定性高达 95% 以上,最长可达 4 小时。该制剂还在体外显示出与 HA 颗粒的高亲和力,Kd = 907 ± 14 mL/g。在正常 Wistar 大鼠体内进行的临床前生物分布研究表明,该复合物可迅速且几乎完全在骨骼中蓄积。对一名患者进行的 PET-CT 成像证实,该复合物能够检测到小的转移性骨骼病变。结论:新合成的[68Ga]Ga标记的NOTA共轭双膦酸盐是一种很有前途的放射性示踪剂,可用于骨骼转移灶的PET-CT成像。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Synthesis, Quality Control, and Bench-to-Bed Translation of a New [68Ga]Ga-Labeled NOTA-Conjugated Bisphosphonate for Imaging Skeletal Metastases by Positron Emission Tomography.

Background: Early detection of skeletal metastasis is of great interest to determine the prognosis of cancer. Positron emission tomography-computed tomography (PET-CT) imaging provides a better temporal and spectral resolution than single photon emission computed tomography-computed tomography (SPECT-CT) imaging, and hence is more suitable to detect small metastatic lesions. Although [18F]NaF has been approved by U.S. FDA for a similar purpose, requirement of a medical cyclotron for its regular formulation restricts its extensive utilization. Efforts have been made to find suitable alternative molecules that can be labeled with 68Ga and used in PET-CT imaging. Objective: The main objective of this study is to synthesize and evaluate a new [68Ga]Ga-labeled NOTA-conjugated geminal bisphosphonate for its potential use in early detection of skeletal metastases using PET-CT. Methods: The authors performed a multistep synthesis of a new NOTA-conjugated bisphosphonic acid using thiourea linker and radiolabeled the molecule with 68Ga. The radiolabeled formulation was evaluated for its in vitro stability, affinity for hydroxyapatite (HA) particles, preclinical biodistribution in animal models, and PET-CT imaging in patients. Results: The bifunctional chelator (NOTA)-conjugated bisphosphonate was synthesized with 97.8% purity and radiolabeled with 68Ga in high yield (>98%). The radiolabeled formulation was found to retain its stability in vitro to the extent of >95% up to 4 h in physiological saline and human serum. The formulation also showed high affinity for HA particles in vitro with Kd = 907 ± 14 mL/g. Preclinical biodistribution studies in normal Wistar rats demonstrated rapid and almost exclusive skeletal accumulation of the complex. PET-CT imaging in a patient confirmed its ability to detect small metastatic skeletal lesions. Conclusions: The newly synthesized [68Ga]Ga-labeled NOTA-conjugated bisphosphonate is a promising radiotracer for PET-CT imaging for skeletal metastases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.80
自引率
2.90%
发文量
87
审稿时长
3 months
期刊介绍: Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信